The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer.

Front Oncol · 2021 · PMC8130554 · PMID 34017688

Europe PMC DOI

hedged sentence

0.0930

closest p · 1.9× alpha

0.0930

boldest claim

The sentences

showed a trendP =0.093so close (0.05 < p ≤ 0.1)

Patients harboring both vimentin and PD-L1 negative expression (<1%) showed a trend towards better survival than those with ≥1% expression (HR=2.31; 95% CI: 0.87-6.17, P =0.093).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.